GHRP-6 draws more searches than any growth-hormone secretagogue this site had yet written about, and it is the one where the published record is thinnest. That gap is the page.
This is research journalism. It reports what the sources state, including the amounts used in trials where those are on the record, each figure carrying its source and date — and it never tells anyone what to take.
What it is
GHRP-6 is a chain of six amino acids, made in the 1980s during the search for compounds that would make the pituitary release its own growth hormone rather than supplying growth hormone from outside. It binds the growth hormone secretagogue receptor — which was later found to be the receptor for ghrelin, the hormone the stomach releases when it is empty. That places GHRP-6 in the ghrelin-agonist half of the secretagogue category, alongside ipamorelin and hexarelin, and not in the releasing-hormone half where sermorelin, CJC-1295 and tesamorelin sit.
It contains no growth hormone and is not growth hormone. It is a signal to release some.
The registry count is zero, and that took classifying to establish
An intervention search of ClinicalTrials.gov for GHRP-6 returns nothing. Not a terminated trial, not a withdrawn one, not a phase I in ten volunteers. Zero.
Searching the spelled-out name — growth hormone releasing peptide 6 — returns 40 studies, and that number is the trap. Reading their titles disposes of all of them: a food-intake decision study, an isocaloric high-protein diet trial, livoletide in Prader-Willi syndrome, ghrelin suppression by octreotide, a sleeve-gastrectomy physiology study, acupuncture for functional dyspepsia, two breast cancer trials, a coffee-and-appetite study, and a deafness-gene screening cohort. The registry matches the words, not the molecule. Not one of the 40 administers GHRP-6.
This is the third compound on which that check has changed the answer here. IGF-1 LR3 returned zero registrations under either naming variant; CJC-1295 returned one, terminated; ipamorelin three. The pattern across the ghrelin-agonist and releasing-factor compounds sold for muscle is consistent, and GHRP-6 sits at the bottom of it.
785 papers, and the biggest block of them is about the opposite drug
The PubMed count for GHRP-6 is 785 records, which sounds like a well-studied compound. It is not what it looks like.
290 of those records — 37% — are about [D-Lys3]-GHRP-6. That is the same hexapeptide with one substitution, and the substitution reverses what it does: it is an antagonist, used in laboratories to switch ghrelin signalling off. It appears in obesity models, diabetes models and inflammation models, and in most of them the researchers are trying to block the receptor, not stimulate it.
So more than a third of the literature that gets cited as GHRP-6's evidence base is research into a molecule designed to do the opposite. That is not a subtlety. A citation count that includes it is measuring the wrong thing, in the same way that counting "creatine" in paper titles sweeps in creatine kinase, and searching creatine with hydrochloride returns four unrelated drugs that happen to be hydrochloride salts.
What the 24 randomised trials measured
Filtering the literature to randomised controlled trials leaves 24 records. Their subjects and endpoints:
| What was studied | Records |
|---|---|
| Pituitary provocation tests in patients — Cushing's disease, thyrotoxicosis, hypothyroidism, acromegaly, non-insulin-dependent diabetes, obesity, GH-deficient children | the majority |
| Animals — steers, cattle, dogs with pituitary-dependent hyperadrenocorticism, streptozotocin-diabetic rats | several |
| Other compounds carried along by the search — MK-677, hexarelin, Tyr-Ala-hexarelin, GHRP-2 | several |
| Muscle, strength, hypertrophy or body composition in healthy adults | none |
The dominant use is diagnostic. A single dose is injected, blood is drawn on a schedule, and the size of the growth-hormone response tells a clinician whether the pituitary is working. That is a laboratory test, not a treatment, and it is what almost the entire human record of this compound consists of.
Nothing here says GHRP-6 does not work. It says nobody has run the study.
The finding that matters most for a lifter: it raises cortisol
One result deserves to be pulled out, because it cuts against the reason the compound is bought.
At the Max Planck Institute of Psychiatry, healthy men received four 50-microgram intravenous boluses of GHRP-6 or placebo across a night, with hormones sampled from 20:00 to 07:00 (PMID 7617137, 1995). Growth hormone rose, as expected: 15.4 ± 9.6 ng/ml against 5.5 ± 4.0 on placebo. So did two other things:
- ACTH: 21.0 ± 5.3 pg/ml against 16.6 ± 3.1 on placebo (p<0.02)
- Cortisol: 56.0 ± 31.0 ng/ml against 25.2 ± 9.0 on placebo (p<0.02)
Cortisol roughly doubled. The authors stated the comparison plainly: this effect is opposite to the blunting of cortisol seen after GHRH. Two compounds that both raise growth hormone move the body's principal catabolic hormone in opposite directions.
This is not a footnote about an obscure molecule. It is the reason the next generation of this class exists: the ipamorelin development programme's selling point was releasing growth hormone without the cortisol and prolactin rises that the earlier ghrelin agonists produced. GHRP-6 is the compound they were designed to improve on, and the improvement was on this exact axis.
A second human finding, from Belgrade in the same year, is worth recording alongside it: GHRP-6's growth-hormone response, alone or combined with GHRH, does not decline in late adulthood (PMID 7734029). That is a real and somewhat unusual pharmacological property. It is a statement about a hormone level, not about muscle.
The only phase III trial, and it is about strokes
There is exactly one late-stage trial of GHRP-6 in the published record, and it has nothing to do with performance.
The COURAGE-2 study, run by Cuba's Center for Genetic Engineering and Biotechnology across five provincial hospitals, gave intravenous epidermal growth factor (75 µg) plus GHRP-6 (5 mg) twice daily for seven days to patients within 12 hours of an acute ischaemic stroke, against standard care (PMID 42462342, Journal of Clinical Neuroscience, October 2026). It enrolled 188 patients, 95 treated and 93 control, mean age 63.5.
It missed its primary endpoint. In the intention-to-treat population there was no difference in disability on the modified Rankin Scale, in the Barthel Index, or in survival. The authors report a signal in a subgroup — 27 patients with severe strokes, NIHSS ≥ 15, where disability and mortality risk were lower — and conclude that further study of that subpopulation is warranted. A subgroup finding in a trial that missed its primary endpoint is a hypothesis, and the authors describe it as one.
The reason this belongs on a performance site is the interest behind it. GHRP-6 has been developed, seriously and at expense, as a cytoprotective agent — something that limits tissue damage. It has never been developed as an anabolic one.
Status: not approved, prohibited in sport
GHRP-6 is not an approved drug for any indication in the United States. It sits in FDA's 503B compounding category 2 — bulk substances presenting significant safety risks — added on 29 September 2023, the same date that swept in several other growth hormone secretagogues.
In sport it is named explicitly on the WADA Prohibited List under S2.2.4 and is prohibited at all times, in and out of competition. The analytical chemistry on catching it is, as with every compound in this class, more developed than the clinical research on whether it works: a nasal-dose study followed one volunteer and detected GHRP-6 in urine for up to 23 hours, and a direct-injection screening method from the Cologne laboratory covers GHRP-1 through GHRP-6 in a single run. The drug-testing page carries the detection windows and the methods in full.
The honest summary
GHRP-6 releases growth hormone in humans. That is established, repeatedly, and it is the only thing about it that is.
Everything else a buyer is likely to assume is unsupported: there is no registered trial, no muscle endpoint in any human study, no body-composition result of any kind, and more than a third of its apparent literature belongs to the molecule that blocks its receptor. The one thing the human data do show beyond a growth-hormone rise is that cortisol goes up with it — which is the specific problem the compound that replaced it was built to solve.
Limits of this page
The registry and literature counts were run on 13 September 2026 and will drift. The classification of the 24 randomised trials was done by reading titles and journals, not full texts, so a muscle endpoint buried as a secondary outcome in a paper whose title does not mention it would have been missed; nothing in the titles suggests one exists. The cortisol result is a single study in healthy men with a small sample, and it is reported here as such.
Sources and dates
- ClinicalTrials.gov API v2, intervention searches for "GHRP-6" and "growth hormone releasing peptide 6", run 13 September 2026.
- NCBI PubMed E-utilities, record counts and publication-type filters, run 13 September 2026.
- Frieboes RM et al. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology 1995;61(5):584–9. PMID 7617137
- Micic D et al. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood. Clin Endocrinol (Oxf) 1995;42(2):191–4. PMID 7734029
- Hernández-Bernal F et al. Phase III open-label, randomized clinical trial of epidermal growth factor and growth hormone releasing hexapeptide in acute ischemic stroke. J Clin Neurosci 2026;152:112195. PMID 42462342
- FDA 503B bulk drug substances category 2 listing, entry dated 29 September 2023.
- WADA Prohibited List 2026, section S2.2.4, as recorded on this site's drug-testing page.